Hiten D. Patel, MD, highlights the background and trial design for the study, “A Prospective Diagnostic Cohort Study to Compare the Accuracy of Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients with Clinically Localized Renal Tumors (BIOPSy)."
In this video, Hiten D. Patel, MD, highlights the background and trial design for the study, “A Prospective Diagnostic Cohort Study to Compare the Accuracy of Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients with Clinically Localized Renal Tumors (BIOPSy),” which was a trial-in-progress abstract being presented at the 2024 American Urological Association Annual Meeting in San Antonio, Texas. Patel is an assistant professor of urology at Northwestern University in Chicago, Illinois.
Lenvatinib plus pembrolizumab delays all organ tumor progression in advanced RCC
June 7th 2024“Overall, our results continue to support the use of lenvatinib and pembrolizumab as a current standard treatment option in the first-line treatment of [patients with] kidney cancer," says Viktor Grünwald, MD, PhD.
Pembrolizumab plus platinum-based therapy shows safety, efficacy in penile cancer
June 4th 2024“The HERCULES trial is the first trial to demonstrate the efficacy of immune checkpoint inhibitors in [patients with] advanced penile cancer with [a] manageable safety profile," says Fernando Cotait Maluf, MD.